Immunotherapy · 2026
Impact of sublingual immunotherapy with dust mite drops on ECP, TARC, VCAM-1 inflammatory status in patients with allergic rhinitis.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Deng Bangyu, Zhao Yunxia, Liu Jisheng
Аннотация
OBJECTIVE: To evaluate the effect of sublingual immunotherapy with dust mite drops on serum eosinophil cationic protein (ECP), thymus and activation-regulated chemokine (TARC), vascular cell adhesion molecule-1 (VCAM-1) levels and symptom improvement in allergic rhinitis (AR) patients.
METHODS: A prospective randomized controlled trial enrolled 300 AR patients sensitized to dust mites, randomly assigned to control group (conventional treatment, n = 150) and research group (conventional treatment plus sublingual dust mite drops, n = 150) for 6 months.
RESULTS: Compared with controls, the research group showed significantly greater reductions in interleukin-4 (IL-4), interleukin-17 (IL-17), ECP, TARC, VCAM-1, lower adverse reaction rates, improved pulmonary function including forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), peak expiratory flow (PEF), FEV1/FVC ratio, and small airway function including maximal mid-expiratory flow (MMEF), expiratory flow rate at 50% of FVC (MEF50), expiratory flow rate at 25% of FVC (MEF25), as well as reduced symptom scores (all p < 0.05).
CONCLUSION: Sublingual immunotherapy with Dust mite drops appears effective in suppressing systemic inflammation, minimizing treatment-related adverse events, enhancing both small airway and pulmonary function, and easing the clinical manifestations of allergic rhinitis.
METHODS: A prospective randomized controlled trial enrolled 300 AR patients sensitized to dust mites, randomly assigned to control group (conventional treatment, n = 150) and research group (conventional treatment plus sublingual dust mite drops, n = 150) for 6 months.
RESULTS: Compared with controls, the research group showed significantly greater reductions in interleukin-4 (IL-4), interleukin-17 (IL-17), ECP, TARC, VCAM-1, lower adverse reaction rates, improved pulmonary function including forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), peak expiratory flow (PEF), FEV1/FVC ratio, and small airway function including maximal mid-expiratory flow (MMEF), expiratory flow rate at 50% of FVC (MEF50), expiratory flow rate at 25% of FVC (MEF25), as well as reduced symptom scores (all p < 0.05).
CONCLUSION: Sublingual immunotherapy with Dust mite drops appears effective in suppressing systemic inflammation, minimizing treatment-related adverse events, enhancing both small airway and pulmonary function, and easing the clinical manifestations of allergic rhinitis.